Taking people in United Arab EmiratesNo phase
Tests patients' own bone marrow stem cells for eye and optic nerve diseases
Tests own bone marrow stem cells in adults with retinal or optic nerve disease.
Key facts
- Who runs it
- MD Stem Cells
- Where
- Dubai, United Arab EmiratesSee the siteAlso in 2 other countries, 3 sites
- Trial code
- Registry title
- Stem Cell Ophthalmology Treatment Study II
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- Jan 2016
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional
- Treatments tested
- Arm 1
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with damage to the retina or optic nerve that is unlikely to improve or is getting worse. It tests treatment with stem cells taken from their own bone marrow.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Documented damage to the retina or optic nerve that is unlikely to improve, or that is progressive. If progressive, central vision of 20/30 or worse in one or both eyes and/or an abnormal visual field in one or both eyes.
- Earlier treatment
- At least 3 months since any eye surgery, and stable. If on medical treatment for a retina or optic nerve disease, the condition must be stable on it.
Main reasons for not taking part
- Cannot have an adequate eye examination to document the problem
- Cannot or will not attend the follow-up eye exams set by the protocol
- Cannot give informed consent
- At significant risk to general health or to the eyes and vision from the procedure
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Have objective, documented damage to the retina or optic nerve unlikely to improve OR
- Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20/30 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes
- Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable
- If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage )
- Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure
- Be over the age of 18
- Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure
- Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health
Who cannot take part
- Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology
- Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol
- Patients who are not capable of providing informed consent
- Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure
Where in United Arab Emirates
Also in 2 other countries, 3 sites
- The Saudi-German HospitalDubai, United Arab EmiratesContact: Steven Levy, MDTaking people
About the trial
What the trial wants to find out
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
The group in the trial
- Arm 1Other group
BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II
- Plain-language title
- Tests patients' own bone marrow stem cells for eye and optic nerve diseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 June 2026